Author

C. Abate-Shen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Approach:statistical model· 2 Approach:deep learning· 1

Frequent Co-Authors

A. Califano· 2 shared A. Vasciaveo· 2 shared B. D. Robinson· 2 shared M. A. Rubin· 2 shared M. Loda· 2 shared M. M. Shen· 2 shared M. Zou· 2 shared T. Pannellini· 2 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Califano

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer

J. J. Li, A. Vasciaveo, D. Karagiannis, Z. Sun, X. Chen, F. Socciarelli, Z. Frankenstein, M. Zou, T. Pannellini, Y. Chen, K. Gardner, B. D. Robinson, J. de Bono, C. Abate-Shen, M. A. Rubin, , M. M. Shen

This study identifies NSD2 as a key driver of lineage plasticity and castration-resistance in neuroendocrine prostate cancer, showing its inhibition can restore sensitivity to AR inhibitors.

bioRxiv · Jul 18, 2023 · PreprintCancer Biology

Distinct mesenchymal cell states mediate prostate cancer progression

H. Pakula, M. Omar, R. Carelli, F. Pederzoli, G. N. Fanelli, T. Pannellini, L. Van Emmenis, S. Rodrigues, C. Fidalgo-Ribeiro, P. V. Nuzzo, N. J. Brady, M. Jere, C. Unkenholz, M. K. Alexanderani, F. Khani, , M. Loda

This study identifies distinct mesenchymal cell states in prostate cancer stroma that correlate with metastatic progression and develops a gene signature to predict patient outcomes.

bioRxiv · Mar 29, 2023Cancer Biology

OncoLoop: A network-based precision cancer medicine framework

A. Vasciaveo, M. Zou, J. M. Arriaga, F. Geraldes de Almeida, E. F. Douglass, M. Shibata, A. Rodriguez-Calero, S. de Brot, A. Mitrofanova, C. W. Chua, C. Karan, R. Realubit, S. Y. Pampou, J. Y. Kim, E. Corey, , C. Abate-Shen

OncoLoop predicts and validates drug sensitivity in tumors and their models by leveraging perturbational profiles of oncology drugs, showing success in prostate cancer models and patient cohorts.

bioRxiv · Feb 11, 2022Cancer Biology